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Abstract
Background: Diabetes is a major challenge for the health care system and especially for the primary care provider. The 
Chronic Care Model represents an evidence-based framework for the care for chronically ill. An increasing number of 
studies showed that implementing elements of the Chronic Care Model improves patient relevant outcomes and 
process parameters. However, most of these findings have been performed in settings different from the Swiss health 
care system which is dominated by single handed practices.
Methods/Design: CARAT is a cluster randomized controlled trial with general practitioners as the unit of 
randomization (trial registration: ISRCTN05947538). The study challenges the hypothesis that implementing several 
elements of the Chronic Care Model via a specially trained practice nurse improves the HbA1c level of diabetes type II 
patients significantly after one year (primary outcome). Furthermore, we assume that the intervention increases the 
proportion of patients who achieve the recommended targets regarding blood pressure (<130/80), HbA1c (=<6.5%) 
and low-density lipoprotein-cholesterol (<2.6 mmol/l), increases patients' quality of life (SF-36) and several evidence-
based quality indicators for diabetes care. These improvements in care will be experienced by the patients (PACIC-5A) 
as well as by the practice team (ACIC). According to the power calculation, 28 general practitioners will be randomized 
either to the intervention group or to the control group. Each general practitioner will include 12 patients suffering 
from diabetes type II. In the intervention group the general practitioner as well as the practice nurse will be trained to 
perform care for diabetes patients according to the Chronic Care Model in teamwork. In the control group no 
intervention will be applied at all and patients will be treated as usual. Measurements (pre-data-collection) will take 
place in months II-IV, starting in February 2010. Follow-up data will be collected after 1 year.
Discussion: This study challenges the hypothesis that the Chronic Care Model can be easily implemented by a 
practice nurse focused approach. If our results will confirm this hypothesis the suggestion arises whether this approach 
should be implemented in other chronic diseases and multimorbid patients and how to redesign care in Switzerland.
Background
Chronic diseases and multimorbidity are the major chal-
lenge for the future health care system [1]. Since chronic
diseases not only impact individuals' quality of life but
also represent a tremendous economical burden, many
approaches have been made to increase patients' quality
of life and to reveal affordable disease management tools.
Based on the evidence of these interventions, summa-
rized in a review of Tsai et al., Wagner and colleagues
developed the Chronic Care Model (CCM) as a concep-
tual framework [2-5]. The aim of the CCM is to integrate
all evidence-based concepts or approaches into this con-
ceptual framework. One of the major problems addressed
by the CCM is the fact that current care of chronically ills
is often reactive and triggered by actual problems instead
of being proactive, structured and planned [6]. Based on
the current evidence, the CCM contains 6 key dimen-
sions of care: Organization of health care, clinical infor-
mation systems, delivery system design, decision support,
self-management support, and community resources.
Most of the data supporting the concept of the CCM
has been collected in settings in the U.S., primarily
HMOs, which do not exist in most European countries.
In Switzerland, the majority of the practices are single
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handed and privately owned. The system is very physi-
cian-centered; practice nurses are only marginally
involved in the diagnostic and therapeutic process. One
reason might be that the proportion between physicians
and inhabitants is very high in Switzerland compared to
other developed countries. As many other countries,
Switzerland is faced with huge demographic changes,
leading to a rising number of older and chronically ill
inhabitants. On the other hand, the number of GPs is
decreasing over many years. Consequently, new, more
team-oriented approaches in the care for chronically ills
are indispensable. Nevertheless, GPs in small, single
handed practices are momentarily the main provider of
care for chronically ills including diabetics in the Swiss
health care system. Large specialist care centers do not
exist; endocrinologists are only used for consultations in
difficult treatment situations. Interestingly, electronic
patient records, an important tool in the treatment and
especially follow-up of chronically ills are not well estab-
lished in Switzerland. As recent data showed, only about
10% of GPs work with electronic patient records (Zoller
et al., Swiss Medical Weekly, submitted). Therefore, it is
unclear if and to what extent the results generated in the
U.S. settings are transferable to Europe or Switzerland in
particular. Due to its widespread acceptance the CCM
has achieved, an intense discussion has started among
European physicians if and how the CCM or its compo-
nents can be implemented in health care [7,8].
Regarding diabetes, valid data on the prevalence in
Switzerland is not available. In Germany for example the
overall prevalence of diabetes for the 25- to 65-year-old
population was 5.34% in 2002-2005 [9] and therefore less
than in the U.S. where the prevalence was estimated to
20.8 million (7% of the population) [10]. Data form the
U.S. show that the expenditures for patients with diabetes
are at a rate 2.3 times higher than those without the dis-
ease [11].
Several studies have shown that there is considerable
potential to improve the process and outcome of diabetes
care in general practice. Some studies showed that 28%
diabetic patients in general practices have poor glycemic
control and 55% have a high body mass index [12]. Struc-
tured programs as the disease management programs
introduced in Germany have shown to improve the qual-
ity of care [13] but results regarding clinical outcomes are
not yet available. Unfortunately, such programs involving
the practice nurse in the treatment have not been
assessed in Switzerland.
Implementing changes in primary care, especially new
concepts of care with the complexity as the CCM, repre-
sents a big challenge. It is well known that strategies to
implement changes in primary care vary widely in their
effectiveness to change clinical practice. For instance,
passive dissemination of information is generally ineffec-
tive for altering health professional behavior [14], while
audit with feedback has a small to moderate effect [15].
Multifaceted interventions targeting different barriers to
change tend to be more effective than single interven-
tions [16]. Educational outreach visits can also change
professionals' behavior [17]. Self management is the pri-
mary goal of diabetes education interventions. Diabetes
associated complications are preventable in most cases.
Research showed that control of glucose (HbA1c), blood
pressure (BP) and low-density lipoprotein (LDL) choles-
terol seem to be the most important targets to avoid
microvascular and macrovascular complications of dia-
betes [18,19].
Diabetes impacts quality of life tremendously [20,21]
and increases the incidence of depression [22], which is
an important comorbidity in most chronic diseases.
Depression or depressed mood has a negative effect on
patients' ability to carry out self-management [23] and
can in consequence worsen the glycemic control [23,24].
Prior studies in diabetes indicated that depression is rec-
ognized and treated in about 33% of patients, even
though psychotherapy and psycho pharmacotherapy have
been shown to have significant beneficial effects on mood
and glycemic control [25-27].
In daily routine an obvious gap between recommenda-
tions and clinical practice can be observed, since the
majority of patients (93%) do not achieve the recom-
mended goals for HbA1c, LDL and BP [28-30]. The fig-
ures vary depending on the observed setting, but it can be
assumed that over one-third of adults have HbA1c levels
above recommended thresholds [29]. Other studies indi-
cated that 32% are above a BP of 130/80mmHg, 66.2%
have LDL values >2.6 mmol/l and nearly a third of the
patients do not receive recommended annual eye (32.3%)
or foot (31.7%) exams [31]. Regarding the thresholds in
this study, we decided to choose a HbA1c level of 6.5%
since the guidelines of the AHA and ADA recommend a
level of 7.0% as general target and a level of 6.0% as ideal
target [32].
This study challenges the hypothesis that implementing
elements of the Chronic Care Model via a specially
trained practice nurse in team work with the general
practitioner improves the HbA1c level of diabetes type II
patients in small, single handed practices in Switzerland
significantly after one year (estimated change: 0.5) and
increases the proportion of patients who achieve the rec-
ommended targets [32] regarding blood pressure (<130/
80), HbA1c (=<6.5%) and LDL-cholesterol (<2.6 mmol/l)
significantly.
Furthermore, we assume that this implementation
improves patients' quality of life (SF-36) and several rele-
vant quality indicators for diabetes care.
Finally we hypothesize that these improvements in care
aiming at a better accordance with the CCM will be expe-Frei et al. Cardiovascular Diabetology 2010, 9:23
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rienced by the patients as well as by the practice team,
reflected in increased scores in the Patient Assessment of
Chronic Illness Care (PACIC-5A) and Assessment of
Chronic Illness Care (ACIC) instruments.
Methods/Design
Outcome-Parameter
The outcome parameters and instruments which are used
in the study are summarized in Table 1.
Primary outcome
The primary outcome is the glycated haemoglobin
(HbA1c) level. The power calculation is based on this
parameter.
Secondary outcomes
Guideline adherence (recommended treatment goals)
The proportion of patients who achieve the recom-
mended targets for diabetes patients [32] regarding blood
pressure (<130/80), HbA1c (=<6.5) and LDL-cholesterol
(<2.6 mmol/l).
Quality of Life (QoL)
Even though the HbA1c is the most common parameter
in diabetes trials, the quality of life is an important out-
come parameter. Furthermore, recent studies have shown
that decreasing the HbA1c aggressively can be associated
with severe side effects, most likely due to hypoglycemia.
In general, disease specific instruments should be favored
against generic instruments, especially due to a higher
sensitivity to change. Regarding diabetes, several instru-
ments to assess QoL have been developed. Since none of
them has so far proven to be superior over the well estab-
lished SF-36 [33], which has already been used in large
diabetes trials in primary care, we decided to use this
instrument.
Quality indicators
Quality indicators can be based on process measures or
clinical outcome measures. To enable international com-
parisons, we decided to asses quality indicators for diabe-
tes according to the recommendations of the American
Diabetes Association [34]. These quality indicators for
diabetes care are also used e.g. by the British National
Diabetes Quality Improvement Alliance. The indicators
reflect the physical examination (incl. feet) and referrals
(incl. eye):
P1: Percentage of patients receiving at least one neph-
ropathy screening per year
Table 1: Outcome-parameters and instruments of the study
Outcome-Parameter (Patient) Parameter/Instrument
Primary Outcome HbA1c level
Secondary outcomes
- Guideline adherence (recommended treatment goals) % of patients reaching goal HbA1c (< 6.5%), LDL-Cholesterol (< 2.6 mmol/
l); blood pressure (< 130/80mmHG)
- Quality of life SF-36
- Process quality
% patients receiving at least one eye examination per year
% patients receiving at least one food examination per year
% patients receiving at least one nephropathy screening per year
% patients receiving at least one neurological testing
- Accordance to the CCM PACIC 5A (patients perspective)
ACIC (provider perspective)
Confounder control PHQ-9 (depression)Frei et al. Cardiovascular Diabetology 2010, 9:23
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P2: Percentage of patients receiving a dilated eye exam-
ination or evaluation of retinal photography by an oph-
thalmologist or optometrist per year
P3: Percentage of patients receiving at least one foot
examination per year
P4: Percentage of patients receiving at least one periph-
eral neurological testing per year
Accordance to the Chronic Care Model (CCM)
Patients' perspective Patients assessment of the pro-
vided care will be assessed with the Patient Assessment of
Chronic Illness Care (PACIC 5A) which has been devel-
oped to assess congruency of provided health care to the
CCM [35]. It is organized according to the key elements
of the CCM and assesses the behavior of professionals
and practice teams from a patient's perspective. The
PACIC 5A contains 20 items assessing 5 scale constructs:
patient activation, delivery system design/decision sup-
port, goal setting/tailoring, problem solving/contextual,
follow-up/coordination. "Patient activation" assesses to
what extent the patient was motivated and supported by
the physician to initiate changes. "Decision support"
assesses if the patient was supported e.g. by booklets and
how satisfied he was with the organization of his care.
"Tailoring" assesses to what extent general instructions
and suggestions were adapted to his personal situation.
"Problem solving" addresses how the physician dealt with
problems which interfered with achieving predefined
goals. Finally, "Follow-up" addresses how frequently and
consequently the whole process was followed-up.
Recently, a German version of the PACIC 5A has been
validated in a sample of osteoarthritis patients [36]. The
"5A" model represents an evidence-based approach to
induce a behavioral change [37]. Glasgow et al. expanded
the PACIC 5A by including 6 items assessing to what
extent physicians' counseling reflects the 5A-approach
which represents the recommended counseling approach
for behavioral changes according to the recommenda-
tions of the US Preventive Services Task Force (USPSTF).
The PACIC 5A was validated in a sample of diabetes
patients [38].
Provider perspective To assess accordance to the CCM
of the health care provider's perspective, the Assessment
o f  Chr o nic I llnes s Ca r e  ( A CIC)  [39]  wil l be  used.  T he
ACIC is aimed at organizational teams to help identifying
areas for improvement in their care for chronic illnesses
and to evaluate the level and nature of improvements
made in their system. It consists of 28 items covering the
six areas of the CCM: Organization of the healthcare
delivery system (6 items), community linkages (3 items),
self-management support (4 items), decision support (4
items), delivery system design (6 items) and clinical infor-
mation systems (5 items). Responses fall within four
descriptive levels (D, C, B, A) of implementation ranging
from D "little or none" to A, a "fully implemented" inter-
vention. Within each of the four levels, respondents are
asked to choose one of three ratings of the degree to
which that description applies. The result is a 0-11 scale,
with categories defined as follows: 0-2 (little or no sup-
port for chronic illness care), 3-5 (basic or intermediate
support for chronic illness care), 6-8 (advanced support)
and 9-11 (optimal, or comprehensive, integrated care for
chronic illness). Subscale scores for the six areas are
derived by summing the response. Bonomi et al. showed
all six ACIC subscale scores to be responsive to health
care quality-improvement efforts [39]. A translated and
culturally adapted version into German (G-ACIC) has
just been validated by the authors (submitted).
Confounder control
Depression has been revealed as a potential confounder
on quality of life and on satisfaction with care in most
chronic diseases, including diabetes. Depression is also
an independent predictor of mortality in many chronic
diseases [40,41]. It also influences the assessment of the
provided care with the PACIC 5A. Thus, depression will
be assessed by means of the Patient Health Question-
naire, short form PHQ-9 [42]. This instrument has been
proven to be a valid and reliable tool and has already been
used in previous studies in primary care as e.g. the Prax-
Art trial [43,44].
Study design
The study is a (prospective) cluster-randomized, open,
two-armed intervention study with the GP as the unit of
randomization. The design of a cluster randomized study
was chosen because this design has optimal internal
validity, while avoiding contamination of interventions
associated with patient randomization. The flow chart of
the study is described in Figure 1.
Sample size
Due to its hierarchical structure, sample size calculations
for cluster randomized trials differ from sample size cal-
culations for common RCTs [45,46]. The required num-
ber of patients increases with the intracluster correlation,
estimated in the intracluster correlation coefficient [47].
Based on our previous studies and on data available at the
website of the University of Aberdeen [48], we assumed
an ICC of 0.04 for the primary outcome. As primary out-
come we defined the HbA1c. The sample size calculation
was performed with the Cluster Randomization Sample
Size Calculator ver.1.02 of the University of Aberdeen.
Unfortunately, no epidemiological data regarding the
HbA1c is available from the Swiss primary care setting.
Based on previous data and on our inclusion criteria
(HbA1c > 7.0%) we assumed a mean HbA1c of 7.7% at
pre-data-measurement time and aimed at a reduction in
the HbA1c of 0.5% points with the intervention. In accor-
dance to the data from the "Diabetes in Germany" (DIG)-Frei et al. Cardiovascular Diabetology 2010, 9:23
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study [49] and the ACCORD trial [50], the SD was
assumed to be 1.2. The power was defined as 80%. The
significance level was defined to be 0.05. Based on these
assumptions and definitions we have to include 12
patients and 11 practices in each arm. In cluster random-
ized trials a higher drop out rate has to be assumed since
the drop out of one cluster leads to the loss of all patients
in a cluster. Therefore we assumed a drop out rate of 20%,
resulting in 14 practices in each arm and 28 in total
[45,46,51].
Recruitment of GPs and randomization
The GPs are the unit of randomization. They are eligible
for randomization if they participate in the routine pri-
mary care of unselected patients to assure that patients of
all social levels have unlimited admission to the practice.
If they are working in a non-single-handed practice, it is
important that they have their own patients which can
clearly be allocated to them. From an address database of
all GPs in the area of Zurich, St. Gallen and Appenzell
every second GP (about 800 GPs in total) was randomly
selected, informed about the study and invited to an
information meeting by a formal letter of the Department
of General Practice and Health Services Research of the
University of Zurich at the end of November 2009. Addi-
tionally, the project was presented in several quality circle
meetings in doctors' networks (regions Zurich, Winter-
thur, St. Gallen). The aim of the information meeting was
Figure 1 Flow chart of the study.
Pre-Data-Measurement
28 Practices, 336 Patients
Randomisation
Control group
14 GPs, 168 Patients
Intervention group 
14 GPs, 168 Patients
CCM - Implementation in 
routine care; structured 
follow-up with the 
CARAT-monitoring-tool
Post-Data-Measurement
28 Practices, 336 Patients
Analysis
training sessions for GPs 
and pratice nurses
T0:February– April
2010
T1: February – April
2011Frei et al. Cardiovascular Diabetology 2010, 9:23
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to provide the GPs with detailed information on the pur-
pose and the associated effort for participating as well as
to give an overview on the course of the whole study. If a
GP was not able to attend the meeting but was interested
in participation, he was invited to contact the Depart-
ment of General Practice and Health Services Research
and was delivered detailed information about the study
by a project assistant.
The GPs who finally agree to participate will be alpha-
betically ordered in a list with numbers from 1 to 28 (no
constraint will be imposed to cluster randomization).
With the statistical program SPSS (version 18.0), 14 fig-
ures out of 28 will be randomly generated which repre-
sent the intervention group. The GPs with the
corresponding numbers will be allocated to the randomly
generated figures and to the intervention group, respec-
tively. The randomization will be performed by an inde-
pendent assistant who is not involved in the study and
who is blind to the identity of the GPs. GPs will be
informed about the group they have been randomized to
after the inclusion of patients has been completed to
avoid any bias in including patients.
Patient inclusion criteria
Eligible patients are identified through the registry based
on laboratory. To be eligible for inclusion patients have to
be adult and diagnosed with diabetes type II according to
the recommendations of the Swiss diabetes society which
is in accordance to the international diagnostic criteria
(Fasting Glucose in blood plasma > 7,0 mmol/l) and a
HbA1c > 7.0%. After an initial letter inviting eligible par-
ticipants to the study the patients are approached during
usual care visits for informed consent. All patients will be
contacted in consecutive order of appearance in the prac-
tice, regardless the reason for the current encounter.
Patient exclusion criteria
1. Patients who are not able to read and understand the
patient information form due to dementia, illiteracy or
insufficient German language skills
2. Patients who contacted the practice for emergencies
only or as a substitute practice
3. Patients with oncological diseases and/or an esti-
m a t e d  l i f e  e x p e c t a n c y  o f  l e s s  t h a n  s i x  m o n t h s  d u e  t o
severe diseases
Data collection
Patients will receive detailed written information on the
aim of the study. After giving their written informed con-
sent they will receive the questionnaire, containing the
SF-36 [33], the PACIC 5A [35,36] and the PHQ-9 [42],
and a stamped envelope with the postal address of the
university. The patients are asked to return this question-
naire in the envelope to the university. Patients will also
be informed that neither the GP nor the practice team
has any possibility to get knowledge of their answers. The
GP will create a list with the participants and allocate a
code to each patient. T his code is also marked on the
questionnaires. The university only receives the patients'
codes and has no access to their names. A second ques-
tionnaire is filled out by the GP and the practice nurse for
each participant regarding current diagnostic findings
(e.g. HbA1c, BD, LDL-cholesterol, weight, pulse etc.),
comorbidities, medication, diabetes associated complica-
tions, compliance, smoking status and quality indicators
for diabetes. This questionnaire is marked as well with
the patient's code and will be returned to the university in
a stamped envelope.
An independent research assistant of the university will
enter the data directly into the SPSS program (version
18.0 or higher). Measurements and analysis will take
place before randomization (pre-data-collection) and
after 12 months (post-data-collection). Pre-data-collec-
tion is estimated to last 3 months (months 2 - 4).
Analysis
We aim to show the reduced level of HbA1c (primary
endpoint) in the intervention group using a t-test for
independent groups comparison. For binary outcome
measures such as success meeting HbA1c, BP and LDL
goals, logistic regression will be used to model the rela-
tionships between the outcome and treatment group, age
and gender. Other potentially important covariates will
be identified through exploratory analyses. The longitu-
d i n a l  a s p e c t  o f  t h e  d a t a  c a n  b e  i n c o r p o r a t e d  i n t o  t h e
model in various ways, we will utilize the model general-
ized estimating equations (GEE) approach [52].
For continuous outcomes such as HbA1c levels, blood
pressure, lipid levels, SF-36 and the PACIC 5A a repeated
measures analysis of variance is appropriate [53]. Fixed
effect parameters will include treatment group, age, gen-
der, and other potentially important covariates as the
PHQ-9 score.
The primary data analysis will follow the intent-to-treat
(ITT) approach where appropriate. This means that all
available data from all individuals will be analyzed
according to treatment group assignment, regardless of
whether or not each individual actually received the
assigned treatment.
Intervention
1. Intervention on the provider of health care
Implementation of complex interventions in a primary
care setting is challenging [54]. Our intervention aims at
providing team care according to the CCM. To perform
care according to the CCM, a team approach involving
the practice nurse is required. This represents a further
challenge since practice nurses are currently only margin-Frei et al. Cardiovascular Diabetology 2010, 9:23
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ally involved in the care for patients. Thus, we performed
a qualitative pre-study with the aim to assess:
1 .  T o  w h a t  e x t e n t  t h e  C C M  o r  i t s  e l e m e n t s  c a n  b e
implemented in general practice in Switzerland [55], and
2. How, and to what extent the practice nurse can be
involved. The interventions reported below (see "clinical
interventions") are carefully adapted to the results of this
study [55].
So, our intervention aims at GPs as well as at practice
nurses. Both are informed about the intervention of the
other group to ease the team approach.
Intervention on the practice nurse In Switzerland, as in
most European countries, the education of practice
nurses differs tremendously from the U.S. and it is com-
pletely unknown if approaches as in the U.S. can be
implemented. The education of practice nurses in Swit-
zerland is less focused on medical issues and addresses
mainly administrative matters. Lacking medical knowl-
edge has been identified as an important barrier towards
an increased involvement of practice nurse in medical
care. Unfortunately, professions as advanced nurse prac-
titioners or physicians' assistants do not or only margin-
ally exist. Therefore, practice nurses represent the only
resource for a team approach in primary care. This study
challenges the hypothesis that CCM appropriate care can
be implemented in primary care. To qualify practice
nurses to do so, practice nurses from the intervention
group will participate in the well established educational
course "Treatment of long term patients - module diabe-
tes" ("Betreuung von Langzeitpatienten - Modul Diabe-
tes"). The course lasts 6 days and will be organized by the
union of Swiss practice nurses ("Schweizerischer Verband
medizinischer Praxisassistentinnen") [56]. The content of
the course is the treatment of diabetes patients (medical
basics, diet, practical tips, communication etc.), the role
of the practice nurse in a team providing structured care
for chronically ills and how to perform a follow-up with
the CARAT-monitoring-tool. The tool addresses clinical
parameters (e.g. HbA1c, blood pressure, LDL etc.), per-
formed examinations (food control, neurological tests,
eye examination etc.) as well as referrals and adherence to
the prescribed drugs and other recommendations. The
tool contains a traffic-light-scheme, indicating if worsen-
ing or improvement has occurred. While giving a quick
overlook over the status, the traffic-light-scheme will ease
the follow-up for the physician who receives the CARAT-
tool after it has been filled out by the practice nurse.
Intervention on the GPs The implementation strategy
consists of two interactive workshops of 4 hours each
including all GPs of the intervention group. The first
meeting will take place immediately after randomization
of the practices, the second one is intended to have some
"booster"-effect and therefore will take place after 3-4
months. In both meetings, the second two hours will con-
tain the GPs as well as the practice nurses to enhance the
team approach. The educational objectives of the two
meetings are evidence-based treatment of diabetes melli-
tus and cardiovascular risk factor management in a pri-
mary care setting, improvement of the team approach in
the practice with focus on the implementation of the
CCM elements and knowledge of the Assessment of
Chronic Illness Care (ACIC) tool including assessment of
the current state in the own practice. The workshops will
be conducted with expert presentations and guided dis-
cussions together with a GP and a practice nurse who are
already experienced in the team approach. Additionally,
GPs will receive a written summary of the concept of the
CCM as well as information on evidence-based treat-
ments of diabetes in a primary care setting.
2. Clinical intervention - Intervention on the patient
The Chronic Care Model has been shown to provide
interactions between patients and providers that support
optimal patient functional and clinical outcomes [57,58].
Practice nurses were chosen to implement and to deliver
the intervention because of the ongoing need for assess-
ment of goal attainment and because of their ability to
work with patients to reduce ambivalence to behavior
change, collaborate with GPs and reinforce diabetes edu-
cation. In the European setting, external nurse practitio-
ners do not exist or are not accepted by GPs. In contrast,
the practice nurses are already integrated in the primary
care setting and have a continuous relationship with
study participants including both direct clinical interven-
tions and collaboration with their GP.
The 6 key elements of the CCM will be addressed as
follows:
Organization of health care: The specially trained prac-
tice nurse will be involved in care. She will monitor the
patient during the study with the CARAT-tool. Contacts
for monitoring are planned at least every 4 moths but the
frequency can be increased according to the clinical situ-
ation of the patient. The clinical aim is to assure that
standing orders for established clinical practice guide-
lines regarding frequency of laboratory testing (HbA1c,
LDL, nephropathy screening), yearly ophthalmologic
exam and performance of foot exam by the nurses facili-
tates are met.
Clinical information systems: The information on mon-
itoring and appointments with the practice nurse will be
collected in the CARAT-monitoring-tool and will be for-
warded to the GP based on importance/urgency before
the patient encounter to the GP. This way of information
transfer between practice nurse and GP is new. This
improvement in communication should help the GP to
get an immediate overview on the current situation of the
patient. It should also help to address current problems -
as for instance a detected depression - more accurately.
Data entry by the nurses into the registry allows the GP toFrei et al. Cardiovascular Diabetology 2010, 9:23
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obtain an overview on self-care goals, clinical parameters
over time (BP , HbA1C, LDL, last ophthalmologic exam,
aspirin use, foot exam) via a single sheet prior to each
patient visit, and provides prompts for issues to be
addressed at a given visit.
For decision support, evidence-based information on
diabetes care and patient information leaflets will be pro-
vided to the GPs during the interactive workshops. The
practice nurses collaborate with the GP by sharing clini-
cal and/or management issues and by providing guideline
recommendations for diabetes [1] and depression [59],
thus supporting the physician in appropriate decisions.
Furthermore, a diabetes specialist of the department of
endocrinology at the University Hospital of Zurich will be
available for GPs to discuss urgent questions regarding
the treatment, to facilitate referrals to specialized care
and to make referrals more appropriate.
Self-management support, another key element of the
CCM, will be addressed by the practice nurses in the fol-
low-up appointments: Basic skills such as glucose moni-
toring, insulin administration, teaching about diabetes
and its complications, and features of medical nutrition
therapy are taught to the study participants with an
emphasis on the patient's own life priorities and internal
motivations. The aim is to assist the patient in selecting
appropriate, concrete behavioral goals, in developing
plans for reaching those goals and in evaluating the prog-
ress and adequacy of those plans. Specific behavior goals
are based on ADA Clinical Guidelines [19] and include
(a) dietary adherence, (b) moderate exercise 30 min for 3
days/week, adjusted for patient ability, (c) medication
adherence and (d) monitoring.
To inform the patient about community resources,
information leaflets will be provided by the practice
nurses.
Individualized patient follow-up: Nurse case managers
meet individually with patients in the treatment group
throughout the study. On average, one hour is spent in
each patient visit, with telephone and e-mail correspon-
dence supplementing office visits where appropriate. Fol-
low-up visits include reinforcement of behavior change
goals, clinical assessments and attainment of clinical
goals.
Timeframe of the study
The recruitment of the practices will start in December
2009. The patient inclusion will take part in the first quar-
ter of 2010. The interventions/courses will start in April
2010. Assessments will be made as described above, T1
measurement will be performed one year after the T0.
Description of risks
Serious risks or undesired effects of the CCM or the
assessment by questionnaires have not been described in
the literature. The clinical diabetes therapy will be ori-
ented according to the available evidence. There are no
specific risks related to the study.
Ethical principles
The study is being conducted in accordance with medical
professional codex and the Helsinki Declaration as of
1996 as well as Data Security Laws.
Study participation of patients is voluntary and can be
cancelled at any time without provision of reasons and
without negative consequences for their future medical
care.
Patient informed consent
Previous to study participation patients receive written
and spoken information about the content and extent of
the planned study; for instance about potential benefits
for their health and potential risks. In case of acceptance
they sign the informed consent form.
In case of study discontinuation all material will be
destroyed or the patient will be asked if he/she accepts
that existing material can be analyzed in the study.
Vote of the ethics committee
The study protocol has been approved by the ethics com-
mittee of the Kanton Zurich and received an unrestricted
positive vote on 25.01.2010.
Data security/disclosure of original documents
The patient names and all other confidential information
fall under medical confidentiality rules and are treated
according to appropriate Federal Data Security Laws. The
results of the patient questionnaires are not accessible to
the GPs. Questionnaires are directly mailed to the study
centre by the patient.
All study related data and documents are stored on a
protected central server of the University of Zurich. Only
direct members of the internal study team can access the
respective files.
Intermediate and final reports are stored in the office of
the Department of General Practice and Health Services
Research at the Zurich University Hospital (USZ).
Discussion
Chronic conditions and multimorbidity represent the
major challenge for the health care systems in the indus-
trialized world. The CCM provides a proactive, patient-
centred, evidence-based approach to face this challenge.
In many recent studies, positive results on patient rele-
vant outcomes could be shown. Adam et al. showed in a
metaanalyses that patients with asthma, receiving care
that included at least two elements of the CCM, were less
often hospitalized and had less emergency encounters
[60]. Nutting et al. showed that the implementation of
CCM elements could be performed in single handed pri-Frei et al. Cardiovascular Diabetology 2010, 9:23
http://www.cardiab.com/content/9/1/23
Page 9 of 11
mary care practices without major efforts or structural
changes. This implementation improved clinical parame-
ters as well as process parameters [61]. In another study,
Parchman et al. showed that the extent to which care
complies with the CCM is a predictor for coronary vessel
disease in a 10 year time frame [62]. Vargas et al. showed
that the care according to the CCM is able to improve risk
factors for cardiovascular diseases in a sample of patients
with diabetes [63]. Based on the growing evidence that
the CCM or at least some of its elements have positive
effects on patients' health, the recent literature contains
recommendations to arrange care according to the CCM
for CVD patients [64], diabetics [62] but also patients
with depression [65].
Taking into account the increasing evidence regarding
the effects of the CCM, the German Society for General
Practice and Family Medicine (Deutsche Gesellschaft für
Allgemein- und Famillienmedizin; DEGAM) has
launched a position paper during its annual meeting in
autumn 2006. In this statement, the CCM has explicitly
been suggested as template for the care for chronically ills
in Germany [7,8]. But even the evidence for the CCM is
growing worldwide, it has to be acknowledged that these
data haven been retrieved in health care systems which
differ in many aspects from the German health care sys-
tem. The resources regarding medical professionals as
nurse practitioners are completely different in Switzer-
land compared to the U.S., for example. But these profes-
sionals play an important role in the CCM. So far, no
experiences are available with implementation of the
CCM in the Swiss health care system. Furthermore, the
CCM has been evaluated regarding diabetes in HMOs,
data from small, singled handed primary care practices
are not available.
Therefore, this study will assess if the CCM can be
implemented in the Swiss health care system as well as if
the CCM can improve the diabetes treatment. Positive
results could not only impact current diabetes treatment
but also enhance the discussed team orientation in pri-
mary care.
The primary goal of the CARAT trial is to evaluate the
effectiveness of an enhanced case management provided
by the practice nurse to improve clinical and psychologi-
cal outcomes in patients with diabetes in primary care
setting, thus determining the impact and sustainability of
the intervention on glycemic and lipid control over 1 year.
The intervention is designed to incorporate aspects of the
CCM with the addition of self-management support
through education. In addition, extensive nurse training
and increased attention to clinical care guidelines will
improve outcomes. The study addresses important ques-
tions regarding the use of nurse case managers in overall
diabetes care, the role of health care providers to initiate
or intensify therapy when indicated, and the psychosocial
effects of diabetes on emotional distress, quality of life
and self-care behaviors.
Limitations
It should be acknowledged that the sample of GPs is asso-
ciated with some kind of selection bias because only GPs
who are interested in the topic might have intended the
information meeting. Such a selection bias can not be
avoided since participation is based on GPs free choice. It
might also not limit the implications of an assumed posi-
tive result for daily practice: If a significant difference
could be achieved in this group of GPs who might be
m or e  fa m iliar  wit h or/ an d i n t e r es t ed in dia bet es t r ea t -
ment it could be assumed that this effect could also be
observed if the intervention is implemented in regular,
weaker performing GPs practices. The threshold for sig-
nificance is higher since we are comparing the interven-
tion group with an assumable already well performing
control group.
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controlled trial; QoL: quality of life.
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